Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 502

• Price / Volume Information    Yesterday's Closing Price: $9.82 Daily Weekly Monthly 20 Day Moving Average: 819,456 shares Shares Outstanding: 134.31 (millions) Market Capitalization: $1,318.95 (millions) Beta: 52 Week High: $28.70 52 Week Low: $7.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.10% 12.75% 12 Week -25.61% -18.21% Year To Date -39.83% -26.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President; Chief Executive Officer and Director Patrik Jeanmonod - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Feng Deng - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/01/22 Share - Related Items Shares Outstanding: 134.31 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,318.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.09 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/01/22

• Fundamental Ratios P/E Current FY Estimate: 109.11 Trailing 12 Months: 327.33 PEG Ratio: - Price Ratios Price/Book: 3.24 Price/Cash Flow: 154.20 Price / Sales: 9.51 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -140.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -9.85% ROE 03/31/22 - 1.78 12/31/21 - 3.60 09/30/21 - - ROA 03/31/22 - 1.31 12/31/21 - 2.50 09/30/21 - - Current Ratio 03/31/22 - 10.26 12/31/21 - 13.01 09/30/21 - 14.65 Quick Ratio 03/31/22 - 9.37 12/31/21 - 12.04 09/30/21 - 13.74 Operating Margin 03/31/22 - 3.86 12/31/21 - 5.62 09/30/21 - - Net Margin 03/31/22 - 0.98 12/31/21 - 2.73 09/30/21 - - Pre-Tax Margin 03/31/22 - 1.79 12/31/21 - 4.64 09/30/21 - - Book Value 03/31/22 - 3.03 12/31/21 - 3.03 09/30/21 - 3.02 Inventory Turnover 03/31/22 - 1.73 12/31/21 - 1.70 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©